Issue Date: June 27, 2011
Tesaro Raises Capital For Oncology Portfolio
Tesaro has raised $101 million from venture capital investors. The Waltham, Mass.-based biotech firm was founded in May 2010 by former executives of MGI Pharma, which Japan’s Eisai acquired in 2008 for $3.9 billion. Tesaro has licensed the neurokinin-1 receptor antagonist rolapitant from OPKO Health and small-molecule inhibitors of anaplastic lymphoma kinase from Amgen. Among other things, the money will support Phase III trials of rolapitant, a candidate to prevent chemotherapy-induced nausea and vomiting.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society